Trial intelligence / Profile preview

Liraglutide in Polycystic Ovary Syndrome

2013-003862-15Phase 4Completed

Sponsor: Jens Faber
Start: Nov 2013
Modality: Peptides
Countries: 1

Overview

Phase 4, randomised trial in polycystic ovary syndrome (PCOS) comparing Liraglutide 1.8 mg once daily with Placebo (2 arms). Primary endpoint: Change in thrombin generation (ETP). Started Nov 2013; status: completed.

Drugs

liraglutide

Conditions

polycystic ovary syndrome (PCOS)

Beyond the preview

Go deeper on 2013-003862-15.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2013-003862-15.